Will the asthma revolution fostered by biologics also benefit adult ICU patients?. Issue 8 (26th December 2020)

• Record Type: Journal Article
• Authors: Bourdin, Arnaud; Charriot, Jérémy; Boissin, Clément; Ahmed, Engi; Suehs, Carey; De Sevin, Arthur; Volpato, Mathilde; Pahus, Laurie; Gras, Delphine; Vachier, Isabelle; Halimi, Laurence; Hamerlijnck, Dominic; Chanez, Pascal
• Is Part Of: Allergy. Volume 76:Issue 8(2021)
• Page Start: 2395
• Page End: 2406
• Publication Date: 2020-12-26
• Subjects: asthma -- IL4Ralpha -- IL5 -- severe exacerbation -- T2 airway inflammation; Allergy -- Periodicals; 616.97
• DOI: 10.1111/all.14688
• Languages: English
• ISSNs: 0105-4538

Abstract

Abstract: Purpose: Asthma exacerbations are inflammatory events that rarely result in full hospitalization following an ER visit. Unfortunately, certain patients require prolonged support, including occasional external lung support through ECMO or ECCOR (with subsequent further exposure to other life‐threatening issues), and some die. In parallel, biologics are revolutionizing severe asthma management, mostly in T2 high patients. Methods: We extensively reviewed the current unmet needs surrounding ICU‐admitted asthma exacerbations, with a focus on currently available drugs and the underlying biological processes involved. We explored whether currently available T2‐targeting drugs can reasonably be seen as potential players not only for relapse prevention but also as candidate drugs for a faster resolution of such episodes. The patient's perspective was also sought. Results: About 30% of asthma exacerbations admitted to the ICU do not resolve within five days. Persistent severe airway obstruction despite massive doses of corticosteroids and maximal pharmacologically induced bronchodilation is the main cause of treatment failure. Previous ICU admission is the main risk factor for such episodes and may eventually be considered as a T2 surrogate marker. Fatal asthma cases are hallmarked by poorly steroid‐sensitive T2‐inflammation associated with severe mucus plugging. New, fast‐acting T2‐targeting biologics (already used for preventing asthma exacerbations) have the potential to circumvent steroid sensitivity pathways and decrease mucus plugging. This unmet need was confirmed by patients who reported highly negative, traumatizing experiences. Conclusions: There is room for improvement in the management of ICU‐admitted severe asthma episodes. Clinical trials assessing how biologics might improve ICU outcomes are direly needed.